Document Detail

Carvedilol for the treatment of benign prostatic hypertrophy in patients with heart failure?
MedLine Citation:
PMID:  21962427     Owner:  NLM     Status:  MEDLINE    
Heart failure (HF) and benign prostatic hypertrophy (BPH) are two conditions that commonly coexist in men 60 years and older. Carvedilol is the only β-adrenergic blocker approved for HF that also has additional α1-adrenergic blockade. As α1-adrenergic blockers are used in the treatment of BPH, it is intuitive that carvediolol could improve BPH symptoms. We present a case where carvedilol was replaced with bisoprolol resulting in acute urinary retention. When carvediolol was reinstituted, the patient's symptoms of BPH resolved. Benign prostatic hypertrophy was later diagnosed by digital rectal exam. Six month after reinstituting the carvediolol, the patient remains free of his BPH symptoms. This case suggests that carvedilol may be considered for the management of HF with systolic dysfunction in patients with concomitant BPH thus eliminating the need for an α1-adrenergic blockers.
Colleen K Rohrer; Robert Lee Page; Simon F Shakar; Joann Lindenfeld
Related Documents :
20071597 - Successful viral suppression with subsequent efavirenz-based regimen in hiv-1-infected ...
7761657 - Short-term preoperative treatment in a case of pheochromocytoma.
18547907 - How long is the window of opportunity between adherence failure and virologic failure o...
15670247 - Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for hiv-infected pati...
25386747 - A risk score for predicting pulmonary hypertension in patients with non-transfusion-dep...
17559377 - A single center experience of methotrexate in the treatment of crohn's disease and ulce...
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2011-06-23
Journal Detail:
Title:  Journal of cardiac failure     Volume:  17     ISSN:  1532-8414     ISO Abbreviation:  J. Card. Fail.     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-10-03     Completed Date:  2012-01-17     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  9442138     Medline TA:  J Card Fail     Country:  United States    
Other Details:
Languages:  eng     Pagination:  875-7     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier Inc. All rights reserved.
Division of Cardiology, Department of Medicine, School of Medicine, University of Colorado, Aurora, Colorado, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / administration & dosage,  adverse effects,  therapeutic use*
Bisoprolol / adverse effects*
Carbazoles / administration & dosage,  therapeutic use*
Heart Failure / complications,  drug therapy*,  pathology
Propanolamines / administration & dosage,  therapeutic use*
Prostatic Hyperplasia / complications,  drug therapy*,  pathology
Urinary Retention / chemically induced
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Carbazoles; 0/Propanolamines; 0K47UL67F2/carvedilol; 66722-44-9/Bisoprolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Molecular signatures of end-stage heart failure.
Next Document:  Reactivity of Activated versus Non-activated 2-(Bromomethyl)aziridines with respect to Sodium Methox...